Sign Up for Free!

Continue Analyzing the page and more.

Continue with Google

Already have an Account? Log In

The Trial has ended

Continue Analyzing the page and more.

Upgrade to Pro
Home Daily Intelligence Tracker
    • Plans Blog Contact
    NUNZIA PHARMACEUTICAL Co logo
    NUNZ

    NUNZIA PHARMACEUTICAL Co

    MaveScore 43 Low model confidence
    Last Price US$0.00 As of Jun 15, 2026
    Market Cap US$43400.0 Company size context
    7D Performance 0.00% Past 7 days
    1Y Performance -96.67% Past 12 months
    Model Rating
    Historical model output for research review

    Fundamental data date

    Dec 31, 2022

    1263 days old

    Market price date

    Jun 15, 2026

    1 day old

    Coverage

    12/16

    4 missing model inputs

    Data quality

    Review

    Partial or delayed snapshot

    Transparent research score

    Why the model scores this stock

    MaveScore is a research prioritization score from 0 to 100. It is historical model output for watchlist review, not personalized financial advice.

    MaveScore 43 Low confidence

    Stored data quality

    Freshness and coverage checks

    Stored company inputs are available, but some dates or model fields are older or incomplete.

    12/16 Partial or delayed snapshot

    Quality

    Quality score blends the latest weighted model rank with underlying profitability and dilution ranks.

    13/35 Weak

    Financial Strength

    Financial strength rewards durable profitability, margins, and positive free cash flow.

    25/25 Strong

    Valuation Support

    Valuation favors positive earnings, positive cash flow, and lower price-to-book multiples.

    0/15 Weak

    Momentum

    Momentum highlights research candidates with supportive 3-month and 6-month price regimes.

    5/15 Weak

    Shareholder Alignment

    Shareholder alignment rewards less dilutive share behavior and enough size for liquid research coverage.

    0/10 Weak

    Positive model output

    • Financial strength rewards durable profitability, margins, and positive free cash flow.

    Research risks to review

    • Quality score blends the latest weighted model rank with underlying profitability and dilution ranks.
    • Valuation favors positive earnings, positive cash flow, and lower price-to-book multiples.
    • Momentum highlights research candidates with supportive 3-month and 6-month price regimes.

    MaveScore uses historical model inputs, stored company fundamentals, and stored price context for research support only. Review missing inputs and business-specific risks before acting. Missing inputs right now include net margin, gross margin, free cash flow per share, book value per share.

    Overview Price History News Competitors Earnings per Share Return on Equity Net Margin Share Buyback Leverage Financial Ratio
    Dashboard Funda..tals Deep..lue Prediction Screener Map

    NUNZIA PHARMACEUTICAL Co Overview

    Industry: Drug Manufacturers Specialty & Generic

    Sector: Healthcare

    Nunzia Pharmaceutical Company operates as a pharmaceutical and nutraceutical company. The company owns the right to manufacture, market, and distribute Nunzia, a nutraceutical that treats autism, fragile X, ADHD, PTSD, and other disorders. It offers its products through wholesalers, as well as through its website nunziapharma.com. The company was formerly known as Arizona Gold and Onyx Mining Company and changed its name to Nunzia Pharmaceutical Company in February 2018. Nunzia Pharmaceutical Company was incorporated in 1986 and is based in Long Beach, California.

    NUNZIA PHARMACEUTICAL Co is evaluated using Mavefund's quality framework: growing earnings, durable profit margins, conservative leverage, strong return on equity, and disciplined share repurchases.

    Score

    Price History & Performance

    Review NUNZIA PHARMACEUTICAL Co in context before unlocking the interactive price chart, financial overlays, and downloadable ratio tables.

    Recent News



    NUNZIA PHARMACEUTICAL Co Competitors

    NUNZIA PHARMACEUTICAL Co operates in the Drug Manufacturers Specialty & Generic industry within the Healthcare sector. Unlock the full page to compare peer rankings, valuation quality, profitability, leverage, and growth trends.

    Earnings Per Share

    EPS quality is one of the core Mavefund signals. Sign up to continue into the detailed EPS, ROE, margin, share buyback, leverage, and financial ratio analysis.

    Continue the analysis

    Sign up to unlock ROE, net margin, share buyback, leverage, financial ratios, peer charts, and downloads.

    View plans
    Ticker Image

    NUNZIA PHARMACEUTICAL Co

    US$0.00

    US$43400.0

    0.00%

    -96.67%